Holbrook, New York, March 31, 2020 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (OTC: EMOR) ("Emerald" or the "Company") a high growth diversified health science and technology company, today has entered into a definitive agreement to acquire Carie Health Inc. (“Carie”), a leading telehealth and virtual care technology and service solutions company.
“Founded in 2016, Carie has quickly matured into a fully-proprietary end-to-end telehealth solution capable of scaling up to lead America’s transition to a more consumer friendly, virtual healthcare model,” said Matt Wanderer, Founder and CEO of Carie Health.
Alongside Emerald’s recent acquisition of Bonsa Health, a leading digital pharmacy with same day delivery of Rx medications anywhere in the US, the acquisition of Carie Health creates an integrated healthcare technology company. This unique service combination will meet the growing demand to deliver high-quality healthcare in a virtual setting.
Emerald’s CEO, Ian Parker, notes “Bringing these companies together will make Carie a meaningful part of the solution as America transitions to a digital-first healthcare delivery model, particularly at a time when healthcare providers are increasingly asked to go into work without the proper personal protective equipment (“PPE”)." Parker continued, "While Emerald considered a number of telehealth acquisitions, Carie’s unique physician centric localized provider model positions it as a definitive industry leader.”
“Today’s transaction marks an important milestone in the growth and evolution of Carie. I am proud to support the combined vision of the companies and to align our shareholders' interests under the executive leadership of Mr. Parker. His organization brings the additional financial and operational resources needed to keep pace with an explosive demand for our product” said Matt Wanderer, Founder and Chief Executive Officer of Carie Health.
To learn more about Carie Health, watch Matt Wanderer's recent interview with Cheddar on the floor of the NYSE.
About Carie Health Inc.
Carie Health Inc. (Carie) was formed in 2016 to create a next generation telehealth platform that, in partnership with major medical insurance, set out to radically improve the cost and convenience gap that most Americans experience when it comes to the availability of quality medical care. Carie’s HIPAA compliant virtual care platform allows its members to connect virtually with their doctor, or a local U.S. board-certified doctor 24 hours a day, 7 days a week. Carie Health provides a provider centric telehealth technology platform for healthcare providers wanting to offer personalized telemedicine solutions to their patients. Carie offers a free cloud-based technology solution which enhances any healthcare provider’s practice while boosting patient satisfaction and convenience. In response to the Covid-19 outbreak Carie has waived both onboarding and utilization fees in the interests of public health
For more information please visit: www.carie.com
About Emerald Organic Products, Inc.
Based in New York, Emerald Organic Products, Inc. (OTC: EMOR), is a diversified health sciences company focused on providing consumers with one of the most robust health and wellness offerings available today. Through its subsidiaries, Emerald is dedicated to both bringing to market, and improving access to, holistic and FDA-regulated products and services. These include high-quality dietary supplements from its flagship brand, Pura VidaTM, as well as a forward-looking hospitality and healthcare program known as EmeraldShieldTM, which will provide healthcare professionals with a full suite of solutions to transform healthcare through the lenses of convenience and mobility. In Q4 2019, Emerald Organic Products established Emerald Organic Life Sciences, LLC. to develop biopharmaceutical assets licensed from Amarantus Bioscience Holdings, Inc. (OTC: AMBS). For more information, please visit https://www.emerald-organic.com/. Emerald recently formed a joint venture with Todos Medical USA, Inc (OTC: TOMDF) for the purpose of distributing certain novel coronavirus (COVID-19) test kits.
Forward-looking Statement
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Emerald Organic Products, Inc. does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Attachment